Absci Corp (ABSI) is a leading U.S.-based life-sciences company pioneering innovative drug discovery and bio-manufacturing technologies. This pioneering company combines synthetic biology and computational biology to transform the drug discovery and manufacturing processes, primarily in the therapeutic areas of oncology, neurology, and immunology.
Founded in 2011 and headquartered in Vancouver, Washington, Absci Corp is deeply committed to reinventing the bio-pharmaceutical industry through its integrated, multiscale, and multidisciplinary approach to therapeutic development. This approach enables the company to design, build, and test a wide range of biologics, including proteins, therapeutic antibodies, and next-generation biologics, thereby streamlining the drug development process and reducing the time to market.
With a market capitalization of over $2 billion, Absci Corp debuted on the NASDAQ in July 2021, making an impressive splash in the high-impact biotechnology world. The company focuses on the lucrative pharmaceutical market which is expected to reach more than $1.5 trillion by 2023, proving the potential of their industry-disruptive innovations.
Absci's flagship technology platform, SoluPro™, is a proprietary protein-expression system that allows the production of complex proteins and biotherapeutics. Used in combination with their drug discovery platform, the system allows for the fast and efficient discovery of drug candidates. E. coli-based protein production, contrary to mammalian cells, enables higher yields, faster results and less investment.
The company also boasts of other platforms such as the Integrated Drug Creation Platform, which merges the capabilities of its drug discovery, cell line development, and bio-manufacturing platforms, as well as Protera, a computer-aided drug design (CADD) technology.
Absci Corp's innovative technologies are backed by partnerships with leading pharmaceutical companies like Merck, Genentech, and Eli Lilly. Its business model enables it to generate revenue through platform technology licensing, research collaboration agreements, and milestone and royalty payments based on partner development progress.
Absci’s acclaimed innovations, collaborative capabilities, and their commitment to accelerating the drug discovery process make them a key player in the biopharmaceutical industry. With a promising future, Absci Corp holds the potential to be a game-changer in the field of drug development, revolutionizing not only the process of discovery but also the accessibility of necessary, life-transforming therapeutics.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bank of America Corp DE has acquired 565,999 shares of Absci Corporation (NASDAQ:ABSI), valued at approximately $6.56 million, representing 0.33% of the company. Other institutional investors have also increased their stakes in Absci, with hedge funds and institutional investors collectively owning 52.05% of the stock. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with an average target price of $13.71, significantly higher than its current trading price of $9.74.
Absci (ABSI) announced its intention to start a global, multi-center mid-stage clinical trial for ABS-201, a treatment for endometriosis, in mid-2027. The company expects to initiate this trial to evaluate the drug's efficacy and safety for patients. Access to the full details of this announcement requires a premium subscription.
Needham & Company LLC has reaffirmed its "buy" rating on Absci (NASDAQ:ABSI) and set an $11.00 price target, representing a potential upside of 2.71%. This recommendation comes despite Absci reporting a quarterly loss of $0.21 per share and revenue of $0.32 million, both missing analyst estimates. Institutional investors, including BlackRock Inc. with a significant new position, own over 52% of the company's stock.
Wall Street analysts predict a 28.3% upside for Absci Corporation (ABSI), with a mean price target of $13.6, despite a recent 55.9% gain. While such price targets can be misleading, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) suggest potential upside. Investors are cautioned to treat price targets with skepticism and consider deeper fundamental research.
Absci (ABSI) stock appears expensive when evaluated against its book value, trading at a price-to-book ratio of 6.8x compared to the biotech industry average of 2.2x. This high valuation raises questions about whether the company's pipeline, partnerships, and cash position justify such a premium, especially given that the business is still loss-making. Analysts offer both bullish and bearish perspectives, with some suggesting significant undervaluation while others point to substantial overvaluation based on future growth and partnership prospects.
Squarepoint Ops LLC significantly reduced its stake in Absci Corporation (NASDAQ:ABSI) by selling 228,841 shares in the second quarter, retaining 162,449 shares. This comes despite Absci reporting weaker-than-expected quarterly results, with institutional investors collectively owning 52.05% of the company. Analysts, however, maintain a "Moderate Buy" consensus rating with an average price target of $13.71, exceeding its current trading price.
Shares of hair-loss drug developers like Veradermics (MANE) and Absci (ABSI) are surging as investors look for the "next Ozempic." Veradermics has seen a nearly 500% increase since its IPO, while Absci's stock has more than doubled in 2026, driven by an underserved market and positive clinical results for potential new treatments. However, concerns about clinical uncertainty, out-of-pocket costs, and high competition could limit their growth compared to the GLP-1 drug boom.
Absci Corporation (NASDAQ:ABSI) has received a consensus rating of "Moderate Buy" from brokerages, with eight out of nine analysts recommending a buy and one a sell. The average 12-month price target is $13.71, while the company recently missed quarterly expectations with a $0.21 loss per share and lower-than-anticipated revenue. Institutional investors hold 52.05% of the stock, with several firms increasing their stakes.